• Explore /
  • Poster
  • / Feasibility of HSCT vs consolidation therapy for AML patients aged 60-75 in CR1: A randomized phase III, multicentre EBMT study.

Feasibility of HSCT vs consolidation therapy for AML patients aged 60-75 in CR1: A randomized phase III, multicentre EBMT study.

Abstract Poster

Authors

null

Dietger Niederwieser

Universitatsklinikum Leipzig AoR, Abt. Hamatologie und internistische Onkologie, Leipzig, Germany

Dietger Niederwieser , Bob Lowenberg , Wolfgang E. Berdel , Ronald Brand , Yves Chalandon , Christian Junghanss , Dirk Hasenclever , Mathias Haenel , Georg Maschmeyer , Meinhard Mende , Mohamad Mohty , Gert Ten Ossenkoppele , Jakob Passweg , Herbert Sayer , Johannes Schetelig , Harry C. Schouten , Sebastian Schwind , Matthias Stelljes , Vladan Vucinic , Jan Cornelissen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Sub Track

Acute Leukemia

Clinical Trial Registration Number

EudraCT Number 2007-003514-34

Citation

J Clin Oncol 36, 2018 (suppl; abstr 7045)

DOI

10.1200/JCO.2018.36.15_suppl.7045

Abstract #

7045

Poster Bd #

105

Abstract Disclosures

Similar Posters

First Author: Henry Jacob Conter

Poster

2011 ASCO Annual Meeting

A randomized, phase III trial comparing BuCy and BuFlu as a myeloablative conditioning regimen.

A randomized, phase III trial comparing BuCy and BuFlu as a myeloablative conditioning regimen.

First Author: S. Kim

First Author: Katherine Tarlock

First Author: Jeffrey E. Lancet